The global urology surgical instruments market size was estimated to be USD 11.34 billion in 2023 and is expected to reach at USD 28.1 billion by 2033 with a CAGR of 8.59% during the forecast period 2023-2033. Growing geriatric population, rising prevalence of urological disorders, such as kidney stones, urinary incontinence, & prostate cancer, increasing demand for urology surgical instruments, growing technological advancements, growing adoption of less invasive surgical methods such as laparoscopy & robot-assisted surgery are some of the key factors boosting the market growth.
Increasing launch of advanced technologies is predicted to boost the market growth during the forecast period. For instance, in March 2023, University Hospital, which serves as the main teaching hospital for Rutgers New Jersey Medical School, has introduced a new technique called single port robotic surgery for the treatment of urological cancers and various other medical conditions.
By Product, Endoscope was the highest revenue-grossing segment in the global urology surgical instruments market in 2022 owing to increasing need for less invasive approaches in diagnostic & therapeutic procedures, surge in investments by market players, and rising product approvals by regulatory bodies. For instance, in May 2022, Auris Health, Inc., a subsidiary of Johnson & Johnson, has received FDA clearance for its Monarch robotic surgery system, which can now be utilized for the removal of kidney stones. The company claims that this system is the first and only flexible and versatile robotic solution designed for both urology and bronchoscopy procedures. This FDA clearance aligns with the company's goal of expanding the capabilities of their robotic platform to cover various medical specialties, allowing hospitals to address two different medical conditions using a single device. Additionally, Accessories and consumables is predicted to grow at fastest CAGR during the forecast period owing to the increase in urological treatments globally and rising demand for advanced instruments.
By Application, Chronic kidney diseases (CKD) was the highest revenue-grossing segment in the global urology surgical instruments market in 2022 owing to the growing prevalence of CKD, increasing clinical trials for novel & non-invasive therapies, rising government initiatives, and surge in investment by major market players. For instance, in January 2021, Advanced MedTech Holdings has recently taken the lead in a Series A funding round for Devicare, contributing a total of USD$3 million. This financial support aims to aid Devicare in its endeavors to create groundbreaking urological treatments that integrate nutritional therapy and digital monitoring. By making this strategic investment in Devicare, Advanced MedTech strengthens its product lineup and solidifies its position as a prominent figure in the fields of urology and kidney stone management. Additionally, Urinary Incontinence (UI) and Pelvic Organ Prolapse (POP) is predicted to grow at fastest CAGR during the forecast period owing to the growing number of surgeries performed to treat urine incontinence, increasing awareness regarding incontinence, rising development of advanced technology, surge in demand for urology surgical instruments, increasing POP surgical operations, and growing collaborations within market players.
By End-user, Hospitals & Clinics was the highest revenue-grossing segment in the global urology surgical instruments market in 2022 owing to surge in number of urological procedures performed in hospitals & clinics, growing number of hospitals & clinics, rising demand for technologically advanced instruments. Additionally, Dialysis Centers is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of kidney failure, increasing technological advancements, and growing partnerships & collaborations within market players. For instance, in January 2022, Ascend Wellness Holdings, a laboratory specializing in dialysis testing, has entered into a strategic partnership with Siemens Healthineers. The objective of this collaboration is to enhance the testing capabilities of Ascend's newly established laboratory in California, allowing for expanded testing capacity.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing geriatric populations, growing prevalence of urology disorders, surge in urology equipment purchases by hospitals, rising number of urologists, increasing favourable reimbursement policies, growing healthcare spending on urology disorders, surge in urology procedures, and the increasing launch of advanced technologies. For instance, in September 2022, The VISERA ELITE III surgical visualization platform was unveiled by Olympus Corporation. This advanced system has been developed to meet the requirements of healthcare professionals (HCPs) who perform endoscopic procedures in various medical fields. The performance of minimally invasive treatments like laparoscopic colectomy and laparoscopic cholecystectomy is made possible by VISERA ELITE III's diversity of imaging tasks that are all integrated into a single system. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the Increasing government spending on urology healthcare, rising healthcare infrastructure, surge in medical tourism. growing demand for urological procedures, increasing investments by private & governmental institutions, rising technological advancements, and growing product approvals by regulatory bodies. For instance, in November 2021Brain Navi Biotechnology, a company based in Taiwan, has obtained the CE mark for its robotic-assisted surgical robot, NaoTrac. This certification ensures that the NaoTrac system complies with the necessary safety and performance standards, allowing it to be marketed and used in European countries.
Increasing launch of advanced technologies is predicted to boost the market growth during the forecast period. For instance, in March 2023, University Hospital, which serves as the main teaching hospital for Rutgers New Jersey Medical School, has introduced a new technique called single port robotic surgery for the treatment of urological cancers and various other medical conditions.
By Product, Endoscope was the highest revenue-grossing segment in the global urology surgical instruments market in 2022 owing to increasing need for less invasive approaches in diagnostic & therapeutic procedures, surge in investments by market players, and rising product approvals by regulatory bodies. For instance, in May 2022, Auris Health, Inc., a subsidiary of Johnson & Johnson, has received FDA clearance for its Monarch robotic surgery system, which can now be utilized for the removal of kidney stones. The company claims that this system is the first and only flexible and versatile robotic solution designed for both urology and bronchoscopy procedures. This FDA clearance aligns with the company's goal of expanding the capabilities of their robotic platform to cover various medical specialties, allowing hospitals to address two different medical conditions using a single device. Additionally, Accessories and consumables is predicted to grow at fastest CAGR during the forecast period owing to the increase in urological treatments globally and rising demand for advanced instruments.
By Application, Chronic kidney diseases (CKD) was the highest revenue-grossing segment in the global urology surgical instruments market in 2022 owing to the growing prevalence of CKD, increasing clinical trials for novel & non-invasive therapies, rising government initiatives, and surge in investment by major market players. For instance, in January 2021, Advanced MedTech Holdings has recently taken the lead in a Series A funding round for Devicare, contributing a total of USD$3 million. This financial support aims to aid Devicare in its endeavors to create groundbreaking urological treatments that integrate nutritional therapy and digital monitoring. By making this strategic investment in Devicare, Advanced MedTech strengthens its product lineup and solidifies its position as a prominent figure in the fields of urology and kidney stone management. Additionally, Urinary Incontinence (UI) and Pelvic Organ Prolapse (POP) is predicted to grow at fastest CAGR during the forecast period owing to the growing number of surgeries performed to treat urine incontinence, increasing awareness regarding incontinence, rising development of advanced technology, surge in demand for urology surgical instruments, increasing POP surgical operations, and growing collaborations within market players.
By End-user, Hospitals & Clinics was the highest revenue-grossing segment in the global urology surgical instruments market in 2022 owing to surge in number of urological procedures performed in hospitals & clinics, growing number of hospitals & clinics, rising demand for technologically advanced instruments. Additionally, Dialysis Centers is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of kidney failure, increasing technological advancements, and growing partnerships & collaborations within market players. For instance, in January 2022, Ascend Wellness Holdings, a laboratory specializing in dialysis testing, has entered into a strategic partnership with Siemens Healthineers. The objective of this collaboration is to enhance the testing capabilities of Ascend's newly established laboratory in California, allowing for expanded testing capacity.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing geriatric populations, growing prevalence of urology disorders, surge in urology equipment purchases by hospitals, rising number of urologists, increasing favourable reimbursement policies, growing healthcare spending on urology disorders, surge in urology procedures, and the increasing launch of advanced technologies. For instance, in September 2022, The VISERA ELITE III surgical visualization platform was unveiled by Olympus Corporation. This advanced system has been developed to meet the requirements of healthcare professionals (HCPs) who perform endoscopic procedures in various medical fields. The performance of minimally invasive treatments like laparoscopic colectomy and laparoscopic cholecystectomy is made possible by VISERA ELITE III's diversity of imaging tasks that are all integrated into a single system. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the Increasing government spending on urology healthcare, rising healthcare infrastructure, surge in medical tourism. growing demand for urological procedures, increasing investments by private & governmental institutions, rising technological advancements, and growing product approvals by regulatory bodies. For instance, in November 2021Brain Navi Biotechnology, a company based in Taiwan, has obtained the CE mark for its robotic-assisted surgical robot, NaoTrac. This certification ensures that the NaoTrac system complies with the necessary safety and performance standards, allowing it to be marketed and used in European countries.
Segmentation: Urology Surgical Instruments Market Report 2022 - 2033
Urology Surgical Instruments Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Bn)
Peripheral Systems
- Endoscopy Fluid Flushing Devices
- Insufflators
Envision Systems
- Camera Heads
- Cameras
- Monitors & Displays
- Light Sources
Endoscopes
- Ureteroscopes
- Laparoscopes
- Resectoscopes
- Nephroscopes
- Cystoscopes
Consumables & Accessories
- Catheters
- Guidewires
- Biopsy Devices
- Stents
- Surgical Dissectors
- Stone Baskets/Retrieval Devices and Extractors
- Needle Forceps and Needle Holders
- Drainage Bags
- Dilator Sets and Ureteral Access Sheaths
- Fluid Flushing Devices, Connecting Tubes, Clamps, Overtubes, and Distal Attachments
- Others
Urology Surgical Instruments Market Analysis & Forecast by Application 2022 - 2033 (Revenue USD Bn)
- Oncology
- Urinary Stones
- Benign Prostatic Hyperplasia (BPH)
- Chronic Kidney Diseases (CKD)
- Urinary Incontinence (UI) and Pelvic Organ Prolapse (POP)
- Other
Urology Surgical Instruments Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Bn)
- Dialysis Centres
- Hospitals & Clinics
- Others
Urology Surgical Instruments Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Urology Surgical Instruments Market: Product Estimates & Trend Analysis
8. Urology Surgical Instruments Market: Application Estimates & Trend Analysis
9. Urology Surgical Instruments Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Urology Surgical Instruments Market
12. Europe Global Urology Surgical Instruments Market
13. Asia Pacific Global Urology Surgical Instruments Market
14. Latin America Global Urology Surgical Instruments Market
15. MEA Global Urology Surgical Instruments Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Stryker
- Medtronic
- Olympus Corporation
- Coloplast Group
- Boston Scientific Corporation
- Cook Medical LLC
- Karl Storz GmbH & Co. KG
- Teleflex Incorporated
- Richard Wolf GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 11.34 Billion |
| Forecasted Market Value ( USD | $ 28.1 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
